Last updated on February 2018

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer


Brief description of study

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)

Clinical Study Identifier: NCT02657889

Contact Investigators or Research Sites near you

Start Over

Heather Branin

Birmingham, AL United States

Joyce Schaffer

Scottsdale, AZ United States

Clinical Trial Management Group

Los Angeles, CA United States

Nilson Wu

San Francisco, CA United States

Clinical Trial Management Group

Stanford, CA United States

Julie Castle

Washington, D.C., United States

Kendra Brown

Jacksonville, FL United States

Kathleen Manning

Miami, FL United States

Nesa Downard

Orlando, FL United States

Clinical Trial Management Group

Atlanta, GA United States

Cheryl Landini

Chicago, IL United States

Cheryl Thomas

Covington, LA United States

Panos Konstantinopoulos, MD, PhD

Boston, MA United States

Jeremy Travis

Burlington, MA United States

Meghan Wyse

Detroit, MI United States

Jill Burton

Rochester, MN United States

Jannette Vetere

Morristown, NJ United States

Lori Megherian

Lake Success, NY United States

Nizam Talukdar

New York, NY United States

Nicole Whitman

Chapel Hill, NC United States

Audrie Walls

Charlotte, NC United States

Cancer Information Services

Cleveland, OH United States

Ingrid Block

Oklahoma City, OK United States

Nicole Holloway

Memphis, TN United States

Mythili Shastry

Nashville, TN United States

Lisa Creighton

San Antonio, TX United States

Natalie Salsini

Charlottesville, VA United States

Rylee Johnson

Seattle, WA United States